Emerging concepts in male contraception: a narrative review of novel, hormonal and non-hormonal options.

Service, C. Austin; Puri, Dhruv; Tung-Chin Hsieh; Patel, Darshan P.

Access to reliable contraception is a pillar of modern society. The burden of unintended pregnancy has fallen disproportionately on the mother throughout human history; however, recent legal developments surrounding abortion have sparked a renewed interest in male factor contraceptives beyond surgical sterilization and condoms. Modern efforts to develop reversible male birth control date back nearly a century and initially focused on altering the hypothalamic-pituitary-testes axis. These hormonal contraceptives faced multiple barriers, including systemic side effects, challenging dosing regimens, unfavorable routes of delivery, and the public stigma surrounding steroid use. Novel hormonal agents are seeking to overcome these barriers by limiting the side effects and simplifying use. Non-hormonal contraceptives are agents that target various stages of spermatogenesis; such as inhibitors of retinoic acid, Sertoli cell-germ cell interactions, sperm ion channels, and other small molecular targets. The identification of reproductive tract-specific genes associated with male infertility has led to more targeted drug development, made possible by advances in CRISPR and proteolysis targeting chimeras (PROTACs). Despite multiple human trials, no male birth control agents have garnered regulatory approval in the United States or abroad. This narrative review examines current and emerging male contraceptives, including hormonal and non-hormonal agents.

HORMONE metabolism; HUMAN reproduction; MEN'S health; TRETINOIN; STEROIDS; MEDROXYPROGESTERONE; TESTOSTERONE; MALE contraceptives; CONTRACEPTIVES; LEVONORGESTREL; DRUGS; VASECTOMY; DRUG development; CONDOMS; RETINOIC acid receptors; DIFFUSION of innovations

Therapeutic Advances in Reproductive Health, 2023, Vol 17, p1

2633-4941

Academic Journal

10.1177/26334941221138323